Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. Unlike non-squamous NSCLC, squamous NSCLC rarely harbor epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations for which there are directed ther...

Full description

Bibliographic Details
Main Author: Sarah L Scarpace
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2015-10-01
Series:Drugs in Context
Subjects:
carcinoma
squamous cell
non-small-cell lung cancer
immunotherapy
molecular targeted therapy
antibodies
monoclonal
nivolumab
pembrolizumab
cisplatin
carboplatin
gemcitabine
pemetrexed
ramucirumab
bevacizumab
programmed cell death-1 receptor
avelumab
MSB0010718C
MPDL3280A
MEDI4736
Online Access:http://www.drugsincontext.com/metastatic-squamous-cell-non-small-cell-lung-cancer-nsclc-disrupting-the-drug-treatment-paradigm-with-immunotherapies/

Internet

http://www.drugsincontext.com/metastatic-squamous-cell-non-small-cell-lung-cancer-nsclc-disrupting-the-drug-treatment-paradigm-with-immunotherapies/

Similar Items